Document is current
Any future updates will be listed below
-
Authors
Wang, Qinglin https://orcid.org/0000-0003-0876-8551
Sun, Yuxiang
Li, Jianyu
Li, Zhizong
Yuan, Fangwei
Xia, Zhijun
Meng, Fanchen
Shen, Ziyang https://orcid.org/0000-0002-6923-8338
Shen, Yiyang
Xu, Lin https://orcid.org/0000-0001-6490-1471
Wang, Jie
Chen, Xi https://orcid.org/0000-0002-5807-4219
Liu, Tongyan
Yin, Rong https://orcid.org/0000-0002-9744-4251
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82073235，82372709)
- License Information
-
More Information
Article History
Received: 14 April 2025
Revised: 23 July 2025
Accepted: 13 August 2025
First Online: 25 August 2025
Competing interests
: The authors declare no competing interests.
: All methods were performed in accordance with the relevant guidelines and regulations. Specifically, animal studies were approved by the Institutional Animal Care and Use Committee of Nanjing Medical University (No. IACUC-2020129). All animal studies were complied with the ARRIVE guidelines and were conducted in accordance with the UK Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health Guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978). Experiments involving humans were in accordance with the ethical standards of the committee (institution and national) and with The Code of Ethics of the World Medical Association (Declaration of Helsinki). All patients completed written informed consent prior to study entry. This study protocol was reviewed and approved by the Ethics Committee of Jiangsu Cancer Hospital, located in Nanjing, Jiangsu Province, China.
: Each patient’s consent form has been signed.
